Become an IMR Panelist
IMR Logo

Angina Market - Comprehensive Study Report & Recent Trends By 2032

Angina Market Global by Drug class (Beta blockers, Calcium channel blockers, Nitrates, Angiotensin-converting enzyme inhibitors, Other), Indication (Stable, Unstable), and Region

  • Report ID : 19715
  • Category : Pharmaceutical and Healthcare
  • Format :Excel formatPDF formatWord format
Request Sample

Angina Market Synopsis:

Angina Market Size Was Valued at USD 11.38 Billion in 2023 and is Projected to Reach USD 16.48 Billion by 2032, Growing at a CAGR of 4.2 % From 2024-2032.

The Angina Market includes the growth, production, and commercialization of therapeutic goods designed to treat angina; a clinical condition that is expressed as chest discomfort due to insufficient blood supply to the heart. It is a market of therapeutic drugs and surgical procedures, and diagnosis tools for various forms of angina including stable angina and unstable angina.

The target market, commonly known as the Angina Market, is still expanding because cardiovascular diseases are on the rise globally, and they are the leading cause of death globally. Inactivity, unhealthy eating, smoking, and climbing the obesity line are some of the reasons behind increased incidences of angina. This is made worse by the fact that people in the advanced age category are more susceptible to contracting coronary artery disease – the leading cause of angina. They are eager patients for novel and feasible pharmacological treatments for angina pectoris and for minimally invasive procedures and new diagnostic methodologies as well.

The mainstay of the treatment of angina includes the use of beta-blockers, calcium channel blockers, nitrates, and antiplatelet agents. Advances in drug delivery systems that touch on issues to do with formulations of drugs including extended-release formulations has enhanced patient adherence and productivity. Further, they also know that healthcare providers are now using enhanced diagnostic technologies to ensure expected accurate diagnosis and right treatment planning which includes cardiac imaging and stress testing. stretching each year due to constant research and development and a shifting emphasis on personalized medicine, the Angina Market is set to grow rapidly in the future

Angina Market

Angina Market Trend Analysis:

Advancements in Drug Delivery Systems

  • The Angina market is witnessing significant growth due to advancements in drug delivery technologies. Innovations such as transdermal patches, oral dissolvable films, and nanotechnology-based formulations are gaining preference for their improved bioavailability and reduced side effects. These systems offer controlled and sustained drug release, enhancing treatment effectiveness and patient compliance compared to traditional dosage forms.
  • The rise of precision medicine is paving the way for personalized treatment approaches tailored to individual patient needs. This shift towards targeted and patient-centric therapies further boosts demand for advanced drug delivery methods. These technological advancements are shaping the future of angina pectoris management, making treatment more efficient, personalized, and user-friendly for patients.

Growing Focus on Emerging Markets

  • New opportunities can be found in Asia-Pacific, Latin America, and the Middle East, a promising region for the Angina Market development. An increase in cardiomyopathy incidence observed in these areas, combined with growing expenditure on medical care and better availability of medical facilities has contributed to the need for controlling angina pectoris.
  • The governments in these regions are focusing on cardiovascular health by increasing awareness and investing in new possibilities in the healthcare field. In addition, the increasing acquisition of these markets by global pharmaceuticals is paving the way for the launch of new therapeutic products at comparatively cheaper prices, thus providing growth opportunities to the market.

Angina Market Segment Analysis:

Angina Market is Segmented on the basis of Drug Class, Indication, and Region.

By Drug Class, Beta-blockers segment is expected to dominate the market during the forecast period

  • The Beta Blockers segment is expected to remain the largest segment in the Angina Market during the forecast period because it is one of the most commonly prescribed drugs for the management of anginal symptoms. Beta-blockers are best in controlling the attacks, decreasing heart rate, and decreasing myocardial oxygen demand thus increasing the survival/QOL in patients with both stable and unstable angina. These drugs include propranolol, atenolol, and metoprolol since they are standard and widely prescribed drugs with favourable safety and efficacy profiles. This is another reason why the segment is dominant because the formulation is generic, and that means that beta blockers are easily affordable by anyone.
  • Newer compounds of beta blockers are depicting better patient compliance and treatment results owing to newer formulations like extended-release preparations. The need for beta blockers as a class of drugs for angina is expected to remain strong since cardiovascular disease remains a growing issue across the world.

By Indication, the Stable Angina segment is expected to held the largest share

  • The Stable Angina segment is expected to have the biggest share of the Angina Market because the illness is prevalent among patients with coronary artery illness. Stable angina is identified by exertional chest pain or pain at a specific time that can be managed by the shutter and is among the many persistent diseases. Various medicine such as beta-blockers, calcium channel blockers and nitrates are widely prescribed in management of stable angina for palliation as well as in the delay of the progress of the disease.
  • The reason for higher growth of this segment is attributed to the growing understanding about the symptoms indicating potential stable angina and the evolving technology in diagnostics. The accrual and dissemination of a variety of treatments from life style changes to pharmacologic management of LUTS enhances patient management. Stable angina is expected to continue to dominate the current market as the healthcare providers and policymakers focus on preventive cardiology.

Angina Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

  • North Americ’s dominance is contributing largely to the high incidences of cardiovascular conditions in the region resulting from poor lifestyles, poor diet, and increased life spans. USA occupies the leading position in the market due to the combined effect of the highly developed system of healthcare, the broad use of up-to-date diagnostic methods, and interest in the cardiovascular research.
  • The continually improving reimbursement policies and high patient awareness level regarding the appropriate diagnosis and treatment of angina also provide thrust to the North American market. These circumstances make region leading in the market because of the presence of such companies as major players which have been posting steady progress in developing various therapies. Due to the increase in healthcare costs and development in the treatment procedures, North America is expected to sustain the leading position in the Global Angina Market.

Active Key Players in the Angina Market

  • Abbott Laboratories (USA)
  • Amgen Inc. (USA)
  • AstraZeneca (UK)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb (USA)
  • Boehringer Ingelheim (Germany)
  • Daiichi Sankyo Co., Ltd. (Japan)
  • Eli Lilly and Company (USA)
  • GlaxoSmithKline plc (UK)
  • Johnson & Johnson (USA)
  • Merck & Co., Inc. (USA)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (USA)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan), and Other Active Players

Angina Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 11.38 Billion

Forecast Period 2024-32 CAGR:

4.2 %

Market Size in 2032:

USD 16.48 Billion

Segments Covered:

By Drug Class
  • Beta-blockers
  • Calcium channel blockers
  • Nitrates
  • Angiotensin-converting enzyme inhibitors
  • Other

By Indication
  • Stable
  • Unstable

By Region
  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:
  • Increasing prevalence of cardiovascular diseases globally.

Key Market Restraints:
  • High cost of advanced therapies and diagnostic tools.

Key Opportunities:
  • Expanding access to angina treatments in emerging markets.

Companies Covered in the report:
  • Abbott Laboratories (USA), Amgen Inc. (USA), AstraZeneca (UK), Bayer AG (Germany), Bristol-Myers Squibb (USA), and Other Active Players.

Frequently Asked Questions :

What would be the forecast period in the Angina Market research report?
The forecast period in the Angina Market research report is 2024-2032.
Who are the key players in the Angina Market?
Abbott Laboratories (USA), Amgen Inc. (USA), AstraZeneca (UK), Bayer AG (Germany), Bristol-Myers Squibb (USA), Boehringer Ingelheim (Germany), Daiichi Sankyo Co., Ltd. (Japan), Eli Lilly and Company (USA), GlaxoSmithKline plc (UK), Johnson & Johnson (USA), Merck & Co., Inc. (USA), Novartis AG (Switzerland), Pfizer Inc. (USA), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), and Other Active Players.
What are the segments of the Angina Market?
The Angina market is segmented into Drug class, Indication, and region. By Drug Class, the market is categorized into Beta blockers, Calcium channel blockers, Nitrates, Angiotensin-converting enzyme inhibitors, and others. By Indication, the market is categorized into Stable and unstable. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
What is the Angina Market?
The Angina Market includes the growth, production, and commercialization of therapeutic goods designed to treat angina; a clinical condition that is expressed as chest discomfort due to insufficient blood supply to the heart. It is a market of therapeutic drugs and surgical procedures, diagnosis tools for various forms of angina including stable angina and unstable angina
How big is the Angina Market?
Angina Market Size Was Valued at USD 11.38 Billion in 2023 and is Projected to Reach USD 16.48 Billion by 2032, Growing at a CAGR of 4.2 % From 2024-2032.
Request Sample

Related Reports

Services Designed to Meet Your Priorities

Understand your customers' needs so can deliver better services and experiences.

Show more

Subscribe to our Newsletter

Stay in touch with us to get latest news and discount coupons.